EUVIMED · CrossrefJournal
AME Clinical Trials Review
ISSN 3005-6152 · AME Publishing Company
Latest articles
Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?
EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer
Precision in practice: a new standard in early-relapsing HR+ breast cancer
Extensive-stage small cell lung cancer: progress, slowly but surely
Where are we LEAPing with anti-angiogenics and immunotherapy combinations?—reflections from the LEAP-008 study
Less is more: lessons from adding antiangiogenesis to 1L chemo-immunotherapy in non-small cell lung cancer (LEAP-006)
We will not have to wait—building regulatory confidence in early endpoints for high-risk breast cancer
Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2
Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon
The dry retina paradox: interpreting MERLIN in clinical practice
Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?
A literature review and reflection on clinical trials: current challenges, future directions, and potential strategies to overcome practical barriers
Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
Steroid-limited isatuximab-based quadruplet therapy in elderly, transplant-ineligible multiple myeloma: a REST trial commentary
Not so fast—should neoadjuvant chemotherapy be routine in resectable pancreatic cancers?
Current and around-the-corner therapies in platinum-resistant ovarian cancer: an insight into the ROSELLA study
Cachexia, cytokines, and caution: lessons from tocilizumab in advanced pancreatic ductal adenocarcinoma
Revisiting CDK4/6 inhibition and SERDs: EMBER-3 and the path forward
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
Targeting the TGF-β pathway in patients with non-small cell lung cancer
Towards better outcomes: segmentectomy for ground-glass opacity-dominant non-small cell lung cancer 3 cm or less—insights from JCOG1211
Changing the way we treat KRAS G12C non-small cell lung cancers
Pafolacianine for imaging of pulmonary neoplasms: a promising supplement for modern surgical technique
Segmentectomy for partially solid non-small cell lung cancer: what counts—the resection or the patient?
The importance of long-term safety, tolerability, and health-related quality of life: lessons from the ADAURA trial
Real world data are needed to establish safety of adjuvant immune checkpoint inhibitors after pneumonectomy
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Two-year analysis of CodeBreaK 100 phase I/II trial: achieved goals of an ongoing challenge
Overall survival of ADAURA: game, set, and match?
EUVIMED